Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04129346 · ClinicalTrials.gov registry record · NA
Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT04129346: Completed NA study, sponsored by Northwestern University.
NCT04129346 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04129346, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study will test the feasibility and acceptability of increasing PA in metastatic breast cancer (MBC) patients using a smartphone app, fitbit and coaching.
Primary Outcome
Feasibility will be assessed via participant retention during the intervention period \[(# of participants randomized- # of participants who drop out or are lost to follow-up)/ # randomized\].
Interventions
- BEHAVIORAL Fitbit
- BEHAVIORAL Fit2ThriveMB App
- BEHAVIORAL Physical Activity Coaching Calls
- BEHAVIORAL Healthy Living Coaching Calls
- BEHAVIORAL Cancer.net app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2021-05-01 |
| Phase | NA |
What the finished NCT04129346 record still lists
NCT04129346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Fitbit is the first listed.
NCT04129346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04129346 about?
NCT04129346 is a clinical study titled "Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB". This study will test the feasibility and acceptability of increasing PA in metastatic breast cancer (MBC) patients using a smartphone app, fitbit and coaching.
What is the current status of trial NCT04129346?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2019-11-26. Estimated completion is 2021-05-01.
What interventions are being tested in trial NCT04129346?
The interventions under investigation include: Fitbit (BEHAVIORAL), Fit2ThriveMB App (BEHAVIORAL), Physical Activity Coaching Calls (BEHAVIORAL), Healthy Living Coaching Calls (BEHAVIORAL), Cancer.net app (BEHAVIORAL).
Who is sponsoring clinical trial NCT04129346?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04129346's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI